AHA Coding Clinic® for ICD-10-CM and ICD-10-PCS - 2022 Issue 2; Ask the Editor
COVID-19 Pre-Exposure Prophylactic Treatment
What is the correct diagnosis code assignment for an encounter for COVID-19 pre-exposure prophylactic treatment using long-acting monoclonal antibodies, such as tixagevimab and cilgavimab (EVUSHELD™)? ...
Subscribe or sign in to view the full article.
Article Overview
This article covers diagnosis coding for an encounter involving COVID-19 pre-exposure prophylactic treatment with long-acting monoclonal antibodies and the FDA Emergency Use Authorization context behind the service. It is aimed at coders, billers, and other revenue cycle professionals who need to understand how the encounter is classified for reporting purposes. The discussion stays focused on the prophylaxis setting, the clinical and regulatory background, and the relevant diagnosis code category.
Why This Topic Matters
Accurate reporting of preventive encounters affects claim submission, record integrity, and consistent handling of COVID-19-related services. This article helps readers recognize the general coding context for a prophylactic visit without needing to interpret the full guidance on their own.
What You Will Learn
- How a COVID-19 pre-exposure prophylactic encounter is classified for diagnosis reporting
- What general regulatory context is associated with the monoclonal antibody therapy
- Which broad type of prophylactic encounter coding category is addressed by the article
- How this topic relates to COVID-19 preventive service documentation
Who Should Read This
- Medical coders
- Billing specialists
- Revenue cycle staff
- Compliance teams
- Health information management professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com